UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

PloS one, 2021-02, Vol.16 (2), p.e0241651-e0241651

2021

Volltextzugriff (PDF)

FGF21-based pharmacotherapy – potential utility for metabolic disorders

Trends in endocrinology and metabolism, 2014-06, Vol.25 (6), p.303-311

2014

Volltextzugriff (PDF)

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

Diabetes, obesity & metabolism, 2021-03, Vol.23 (3), p.664-673

2021

Volltextzugriff (PDF)

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Cell metabolism, 2013-09, Vol.18 (3), p.333-340

2013

Volltextzugriff (PDF)

Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

Diabetes (New York, N.Y.), 2006-06, Vol.55 (6), p.1695-1704

2006

Volltextzugriff (PDF)

Fibroblast Growth Factor 21 Corrects Obesity in Mice

Endocrinology (Philadelphia), 2008-12, Vol.149 (12), p.6018-6027

2008

Volltextzugriff (PDF)

THE MECHANISMS OF ACTION OF PPARS

Annual review of medicine, 2002-01, Vol.53 (1), p.409-435

2002

Volltextzugriff (PDF)

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319

PloS one, 2013-03, Vol.8 (3), p.e58575

2013

Volltextzugriff (PDF)

Metabolic Disease Drug Discovery— “Hitting the Target” Is Easier Said Than Done

Cell metabolism, 2012-01, Vol.15 (1), p.19-24

Moller, David E.

2012

Volltextzugriff (PDF)

Metabolic syndrome: a clinical and molecular perspective

Annual review of medicine, 2005-01, Vol.56 (1), p.45-62

2005

Volltextzugriff (PDF)

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats

Endocrinology, diabetes & metabolism, 2021-04, Vol.4 (2), p.e00193-n/a

2021

Volltextzugriff (PDF)

Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity

Diabetes/metabolism research and reviews, 2011-03, Vol.27 (3), p.286-297

2011

Volltextzugriff (PDF)

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

Hepatology communications, 2022-01, Vol.6 (1), p.101-119

2022

Volltextzugriff (PDF)

Identification and Characterization of a Major Liver Lysophosphatidylcholine Acyltransferase

The Journal of biological chemistry, 2008-03, Vol.283 (13), p.8258-8265

2008

Volltextzugriff (PDF)

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

Diabetes (New York, N.Y.), 2002-07, Vol.51 (7), p.2074-2081

2002

Volltextzugriff (PDF)

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Journal of lipid research, 2007-07, Vol.48 (7), p.1488-1498

2007

Volltextzugriff (PDF)

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin

Physiological reports, 2022-03, Vol.10 (5), p.e15151-n/a

2022

Volltextzugriff (PDF)

AGPAT6 Is a Novel Microsomal Glycerol-3-phosphate Acyltransferase

The Journal of biological chemistry, 2008-04, Vol.283 (15), p.10048-10057

2008

Volltextzugriff (PDF)

Mice Lacking Dipeptidyl Peptidase IV Are Protected against Obesity and Insulin Resistance

Proceedings of the National Academy of Sciences - PNAS, 2003-05, Vol.100 (11), p.6825-6830

2003

Volltextzugriff (PDF)

New drug targets for type 2 diabetes and the metabolic syndrome

Nature (London), 2001-12, Vol.414 (6865), p.821-827

Moller, David E

2001

Volltextzugriff (PDF)

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Diabetes care, 2016-07, Vol.39 (7), p.1241-1249

2016

Volltextzugriff (PDF)

Lipolysis of Triglyceride-Rich Lipoproteins Generates PPAR Ligands: Evidence for an Antiinflammatory Role for Lipoprotein Lipase

Proceedings of the National Academy of Sciences - PNAS, 2003-03, Vol.100 (5), p.2730-2735

2003

Volltextzugriff (PDF)

Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)

Journal of hepatology, 2023-05, Vol.78 (5), p.914-925

2023

Volltextzugriff (PDF)

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease

Kidney international, 2023-05, Vol.103 (5), p.917-929

2023

Volltextzugriff (PDF)

Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome

Endocrine, 2006-02, Vol.29 (1), p.91-100

2006

Volltextzugriff (PDF)

1 – 25 von 675

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(628)
Mit Volltextzugriff
(580)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action

FGF21-based pharmacotherapy – potential utility for metabolic disorders

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic β-Cell Mass and Function in a Rodent Model of Type 2 Diabetes

Fibroblast Growth Factor 21 Corrects Obesity in Mice

THE MECHANISMS OF ACTION OF PPARS

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319

Metabolic Disease Drug Discovery— “Hitting the Target” Is Easier Said Than Done

Metabolic syndrome: a clinical and molecular perspective

Imeglimin preserves islet β‐cell mass in Type 2 diabetic ZDF rats

Direct effects of FGF21 on glucose uptake in human skeletal muscle: implications for type 2 diabetes and obesity

Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis

Identification and Characterization of a Major Liver Lysophosphatidylcholine Acyltransferase

Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects With Type 2 Diabetes

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin

AGPAT6 Is a Novel Microsomal Glycerol-3-phosphate Acyltransferase

Mice Lacking Dipeptidyl Peptidase IV Are Protected against Obesity and Insulin Resistance

New drug targets for type 2 diabetes and the metabolic syndrome

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Lipolysis of Triglyceride-Rich Lipoproteins Generates PPAR Ligands: Evidence for an Antiinflammatory Role for Lipoprotein Lipase

Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)

A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease

Modulation of fatty acid metabolism as a potential approach to the treatment of obesity and the metabolic syndrome

Suchergebnisse filtern